SMO and neoplasm: Similarly, tumours with an activating mutation in the HH pathway downstream of SMO, such as SUFU loss, or tumours that develop resistance to SMO inhibitors, may be responsive to GANT61 or similar inhibitors that target GLI1 [71–74].